Root cause analysis and lab controls prove to be new compliance headaches for Indian drug makers
Wednesday , February 21 , 2018 - 09:00 PM

Among import alerts or import bans issued by US FDA for more serious compliance issues, Indian sites constituted 30 percent, while China#39;s share was 50 percent in 2017.

View Source

Business News